Multi-peptide blend12 min read

KLOW Blend: What It Is and What It Does

KLOW Blend — research reference vial

Analytical-grade · lot-matched COA

A four-peptide repair-and-inflammation blend (BPC-157 + GHK-Cu + TB-500 + KPV). Below: what KLOW Blend is, what it does in plain terms, and the published studies — for laboratory research use only.

VNG Research TeamJuly 15, 2026Updated July 23, 2026
Class
Multi-peptide blend
Published studies cited
10
Literature span
1997–2026

For research & educational purposes only. This article is a neutral, procedural reference for laboratory / in-vitro research handling — not medical advice or a usage recommendation. These materials are not for human or animal consumption.

On this page

What KLOW Blend is

KLOW is a research blend of four peptides: BPC-157, GHK-Cu, TB-500, and KPV. It is supplied as an analytical-grade reference material for laboratory research.

Where it comes from

KLOW is a research blend rather than a single discovered compound, stacking four separately identified peptides. BPC-157 is a synthetic 15-amino-acid fragment derived in the 1990s from a protein in human gastric juice. GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from human plasma in the 1970s. TB-500 is a lab-made copy of the active region of the repair protein thymosin beta-4. KPV is a three-amino-acid fragment (lysine-proline-valine) from the tail of the hormone alpha-MSH. The blend groups them so researchers can look at repair and anti-inflammatory actions side by side.

What it does — in plain terms

KLOW stacks four compounds with repair and anti-inflammatory angles: BPC-157 and TB-500 (tissue repair and recovery), GHK-Cu (skin and collagen), and KPV (calming inflammation). As with any blend, the research interest is in how the ingredients act together. Each component has its own post with the primary studies.

How it works

KLOW combines four peptides that fall into two research themes: tissue repair (BPC-157 and TB-500) and skin plus inflammation control (GHK-Cu and KPV). They do not share a single receptor; the idea behind the stack is that each covers a different part of the repair-and-inflammation picture. As with any blend, this is a design rationale — the combination itself has not been tested as a unit, and the real evidence sits with the individual ingredients.

On the repair side, BPC-157 is described across preclinical studies as a repair dispatcher that promotes new blood-vessel growth (angiogenesis) largely through the VEGF pathway, so injured tissue is supplied faster. TB-500, the active fragment of thymosin beta-4, binds actin inside cells and is studied for helping repair cells migrate to a wound and for supporting new vessels — a complementary route to a similar goal.

On the skin-and-inflammation side, GHK-Cu is a copper-carrying tripeptide associated in lab work with collagen production and remodeling of the skin's support matrix. KPV, a small piece of alpha-MSH, is studied mainly as an off switch for over-active inflammation, appearing to dial down inflammatory signaling in gut and skin models. The thinking is that BPC-157 and TB-500 handle rebuilding, GHK-Cu the matrix, and KPV the inflammatory tone — but because these effects come from separate literatures, the primary studies live in each component's own post.

What the research shows

A four-peptide blend like KLOW is essentially never studied as a single combination, so the honest picture is that the evidence belongs to the individual ingredients and is largely preclinical. The studies gathered here center on the BPC-157 component, alongside a few broad reviews of injectable peptides in regenerative and orthopaedic research; the GHK-Cu, TB-500, and KPV evidence is covered in their own posts. With that framing, here is what some of that published work reports.

  • Cell and Tissue Research, 2019 — reviewed the BPC-157 component's effects on musculoskeletal soft-tissue healing, describing accelerated tendon, ligament, and muscle recovery in animal models.
  • Frontiers in Pharmacology, 2021 — surveyed the BPC-157 component's role in wound healing across preclinical models.
  • International Journal of Molecular Sciences, 2026 — reviewed the BPC-157 component in tissue-repair and pain research.
  • Current Pharmaceutical Design, 2018 — examined how the BPC-157 component interacts with growth factors during tissue healing.
  • Journal of Applied Physiology, 2011 — found, in a laboratory (cell) study, that the BPC-157 component improved tendon-cell healing, including better cell survival and migration.
  • Arthroscopy, 2025 — reviewed injectable peptides used in regenerative-medicine research — the broader class these blend ingredients belong to — rather than any single component.
  • JAAOS Global Research & Reviews, 2026 — reviewed therapeutic peptides studied in orthopaedics as a general class, providing context for blends like this one.
  • The American Journal of Sports Medicine, 2026 — provided an orthopaedic primer on injectable peptide research generally, not on this blend specifically.
  • Current Pharmaceutical Design, 2014 — examined the BPC-157 component's effects on blood vessels, a recurring angiogenesis theme in its literature.
  • Journal of Physiology, Paris, 1997 — described early research on the BPC-157 component and its healing-related effects.

What KLOW Blend is studied for

Tissue and soft-tissue repair — BPC-157. The BPC-157 component is the most-referenced here, studied in animal models for speeding repair of slow-healing tissue such as tendon and muscle, largely by improving local blood supply.

Wound healing and cell migration — TB-500. The TB-500 component is examined for helping repair cells move into a wound and for supporting new blood-vessel formation; its primary studies are in the TB-500 post.

Skin and collagen — GHK-Cu. The GHK-Cu component adds the skin angle, associated in lab studies with collagen production and remodeling of the skin's support matrix. See the GHK-Cu post.

Calming inflammation — KPV. The KPV component is studied as an anti-inflammatory signal in gut and skin models, appearing to turn down an over-active inflammatory response. Its literature lives in the KPV post.

Storage & handling

As a lyophilized (freeze-dried) powder, this four-peptide reference material is most stable kept cold and dark — refrigerated, or frozen for longer holds. Once reconstituted with bacteriostatic water it should be refrigerated at roughly 2-8 °C, protected from light, and kept away from repeated freeze-thaw cycles, which are especially hard on multi-peptide mixtures. The copper-containing component also warrants avoiding unnecessary warming. See the reconstitution reference below for concentration details.

Plain-language explanations describe what researchers study — not what any product does for a person, and not medical advice. Every material here is sold for laboratory research use only and is not for human or animal use.

Reconstitution reference

Standard laboratory reconstitution volumes for KLOW Blend, from the VNG Reconstitution Sheet. See the full reconstitution guide for the method and concentration math.

ProductVialBacteriostatic waterResulting concentration
KLOW (BPC-157 + GHK-Cu + TB-500 + KPV)80 mg3 mL~26.7 mg/mL

Frequently asked questions

What is KLOW?

KLOW is a research blend of four peptides — BPC-157, GHK-Cu, TB-500, and KPV — grouped around tissue repair and inflammation control. It is supplied here as an analytical-grade reference material for laboratory research use only.

Is the KLOW blend itself supported by human trials?

No. The four-peptide combination has not been studied as a blend in people. The available evidence is on the ingredients individually, and most of it is preclinical (cell and animal) research, so KLOW is best viewed as a research tool rather than a proven combination.

What does each ingredient contribute?

In broad terms: BPC-157 and TB-500 are studied for tissue repair and recovery, GHK-Cu for skin and collagen, and KPV for calming inflammation. Each has its own post with the primary studies; this page focuses on how those mechanisms are thought to combine.

Why put four peptides together?

The rationale is complementary coverage across repair and inflammation. Researchers use blends to observe how components behave alongside one another, but stacking peptides does not by itself guarantee any additional benefit — that would have to be demonstrated in dedicated studies.

How is it handled in the lab?

The GLOW blend ships as a lyophilized powder, stored cold and dark, and is reconstituted with bacteriostatic water for laboratory research. It is a reference material for research use only and is not for human or veterinary use.

Published research

A selection of peer-reviewed and clinical literature indexed on PubMed. Provided so qualified researchers can locate the primary sources — inclusion here is not a claim about any product or outcome.

  1. Peer-reviewed studyCell and tissue research · 2019

    BPC-157 and musculoskeletal soft-tissue healing

    View on PubMed
  2. Peer-reviewed studyFrontiers in pharmacology · 2021

    BPC-157 and wound healing

    View on PubMed
  3. Peer-reviewed studyInternational journal of molecular sciences · 2026

    BPC-157 in tissue repair & pain research

    View on PubMed
  4. Peer-reviewed studyCurrent pharmaceutical design · 2018

    BPC-157, growth factors & tissue healing

    View on PubMed
  5. Lab / formulation studyJournal of applied physiology (Bethesda, Md. : 1985) · 2011

    BPC-157 and tendon-cell healing — lab study

    View on PubMed
  6. Peer-reviewed studyArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025

    Injectable peptides in regenerative medicine — review

    View on PubMed
  7. Peer-reviewed reviewJournal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026

    Therapeutic peptides in orthopaedics — review

    View on PubMed
  8. Peer-reviewed studyThe American journal of sports medicine · 2026

    Injectable peptide therapy — orthopaedic primer

    View on PubMed
  9. Peer-reviewed studyCurrent pharmaceutical design · 2014

    BPC-157 and blood vessels

    View on PubMed
  10. Peer-reviewed studyJournal of physiology, Paris · 1997

    BPC-157 and healing

    View on PubMed

References & resources

Continue reading

Related reference materials

VNG Research Team

VNG Labs supplies analytical-grade reference materials with lot-matched Certificates of Analysis. Our write-ups are neutral, source-cited references for qualified and independent researchers.

More from Learn

Research use only. Not for human consumption or veterinary use. Sold exclusively to qualified researchers for in vitro and laboratory research. These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Refrigerate upon receipt. Keep in dark environment.